Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults

• Published in: Human vaccines & immunotherapeutics Vol. 8; no. 8; pp. 1048 - 1052
• Main Authors: Ansaldi, Filippo, Valle, Laura, de Florentiis, Daniela, Parodi, Valentina, Murdaca, Giuseppe, Bruzzone, Bianca, Durando, Paolo, Setti, Maurizio, Icardi, Giancarlo
• Format: Journal Article
• Language: English
• Published: United States 01.08.2012
• Subjects: Adult; Antibodies, Viral - blood; Antigens, Viral - administration & dosage; Antigens, Viral - immunology; Binding; Biology; Bioscience; Calcium; Cancer; CD4 Lymphocyte Count; Cell; Cycle; Drug-Related Side Effects and Adverse Reactions - epidemiology; Female; Hemagglutination Inhibition Tests; HIV Infections - immunology; Humans; Influenza A Virus, H1N1 Subtype - immunology; Influenza A Virus, H2N2 Subtype - immunology; Influenza B virus - immunology; Influenza Vaccines - administration & dosage; Influenza Vaccines - adverse effects; Influenza Vaccines - immunology; Injections, Intradermal; Injections, Intramuscular; Landes; Male; Middle Aged; Organogenesis; Proteins; RNA, Viral - blood; Vaccines, Inactivated - administration & dosage; Vaccines, Inactivated - adverse effects; Vaccines, Inactivated - immunology
• ISSN: 2164-5515; 2164-554X
• DOI: 10.4161/hv.20347

This study evaluated safety, tolerability and immunogenicity of intradermal (ID) trivalent inactivated split influenza vaccine, with a lower antigen content (9 mcg HA per strain) than the conventional intramuscular one (15 mcg), in HIV-1-infected adults younger than 60 years. A total of 54 HIV-1-positive participants were enrolled and randomly assigned to receive a single dose of either ID-administered low-antigen-content split inactivated vaccine or intramuscularly-administered (IM) standard-dose inactivated split vaccine. Subjects were provided with a diary to monitor any local and/or systemic reactions to the vaccine for 7 days following vaccination. Serum samples were collected before, 28 days and 90 days after immunization. The plasma HIV-RNA and CD4+ T-lymphocyte count were checked at day 0 and day 90. Serum hemagglutination-inhibition (HI) activity for the three influenza strains included in the vaccine composition was measured to assess the antibody response at one month and 3 months after vaccination. Both vaccines showed optimal safety and tolerability profiles. All the three Committee for Medicinal Products for Human Use immunogenicity criteria for vaccine approval in adults younger than 60 were met by both vaccines against A(H1N1) and A(H3N2) viruses. Both vaccines met mean-fold-increase and seroprotection criteria but failed seroconversion criteria against B virus. No difference in terms of post-vaccination geometric mean titers, mean fold increase, seroprotection and seroconversion rates were found comparing ID and IM vaccines. In conclusion, the recently available low-antigen-content ID vaccine is safe, well-tolerated and as immunogenic as IM standard-dose influenza vaccine.